[Ipriflavone in the treatment of osteoporosis].
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
Hiroaki Ohta
Publications and source records attributed to Hiroaki Ohta.
[Effects of genetic factors on the response to hormone replacement therapy].
Hormone Replacement Therapy (HRT) is currently recognized as the potential tool for menopause medicine. But it is also well known that the effects of HRT on bones and blood vessels show interindividual variances. Among the candidate factors to explain these variances, genetic factors may play an important role. Several reports have shown associations between some genetic markers, such as polymorphisms of estrogen receptor alpha gene, and the effect of HRT on bone mineral density. Phenotype of apolipoprotein B, E, and angiotensin-converting enzyme, as well as polymorphisms of estrogen receptor alpha gene, have been reported to influence the lipid metabolic or vasodilatic response to HRT. This information can be applicable to tailor-made therapy. But the results of reports are conflicting and relationships between genetic markers and the response to HRT are still controversial. Further investigations will reveal the potential of genetic markers in disease managements near future.
English Abstract↗
[Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal osteoporosis].
Treatment with etidronate alone is unlikely to increase the bone mineral density of the femoral neck. In combination of etidronate and hormone replacement therapy has been shown to markedly increase the bone mineral density of the femur and may decrease the risk of fracture. These findings suggest that etidronate and hormone replacement therapy inhibit bone resorption by different mechanisms of action. Treatment with a combination of etidronate and hormone replacement therapy may therefore be an important option for the management of postmenopausal osteoporosis.
English Abstract↗
[Hormone replacement therapy and osteoporosis from the perspective of evidence-based medicine].
Preparations of the estrogen (HRT) are considered the gold standard for the prevention and treatment of postmenopausal osteoporosis. However, supporting evidence based on the results of large, prospective, randomized controlled trials of estrogen preparations was largely lacking. In 2001 the results of two major studies were reported. The first was a meta-analysis of 22 randomized studies, and the second was an 11-year survey. Both of these studies provide very reliable evidence. The recently published interim report of the Women's Health Initiative states that the incidence of femoral fractures decreased by 34% in women who received HRT. HRT thus remain one gold standard for the prophylaxis and therapy of osteoporosis.
English Abstract↗
A case of fetal subdural hematoma at 31 weeks of gestation in a woman on warfarin therapy after Cabrol's operation.
The case of a complicated pregnancy of a woman who had undergone Cabrol's operation, and whose baby suffered from subdural hematoma is presented. Although the outcome of this case was not so severe, we would like to inform about the risk to both the mother and her fetus as a result of serious complications.
Adult↗
Mental health of patients visiting an outpatient menopause clinic.
OBJECTIVE: It is understood that psychological factors affect climacteric disturbances. However, details behind these issues remain unknown. The aim of this study was to investigate the mental health of climacteric patients. SUBJECTS AND METHODS: The subjects were 127 Japanese women who visited our outpatient menopause clinic, complaining chiefly of climacteric disturbances. There were 38 premenopausal patients included. The responses to the HADS (Hospital Anxiety and Depression Scale) and the SDS (Self-rating Depression Scale), obtained at the first examination, were compared with HADS data from 2,943 healthy women and 94 patients hospitalized to receive gynecological surgery. RESULTS: The HADS score and the SDS score of the outpatients of the menopause clinic showed a relatively high (statistically significant) correlation. The average HADS total, anxiety and depression scores for these patients were significantly higher than those for healthy controls. The total and depression scores were also significantly higher than those for patients hospitalized to undergo surgery for benign conditions, and were comparable to those for patients with malignant conditions. The comparison between pre- and postmenopausal patients showed that the premenopausal group was more likely to be depressed. The anxiety score was also high in this group (not significantly). CONCLUSIONS: These results indicate that patients with climacteric disturbances, especially premenopausal patients, often experience psychological discomfort, and that attention should be given not only to their depression but also to their anxiety.
Adult↗